| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diagnostic Imaging | 16 | 2023 | 1159 | 2.450 |
Why?
|
| Radiology | 9 | 2021 | 434 | 2.120 |
Why?
|
| Tomography, X-Ray Computed | 27 | 2022 | 7566 | 1.880 |
Why?
|
| Multimodal Imaging | 5 | 2019 | 548 | 1.690 |
Why?
|
| Burnout, Professional | 3 | 2020 | 206 | 1.580 |
Why?
|
| Magnetic Resonance Imaging | 27 | 2023 | 7717 | 1.360 |
Why?
|
| Radiologists | 7 | 2022 | 163 | 1.290 |
Why?
|
| Ovarian Neoplasms | 9 | 2023 | 4660 | 1.250 |
Why?
|
| Kidney Neoplasms | 9 | 2023 | 3018 | 1.170 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2021 | 600 | 1.010 |
Why?
|
| Carcinoma, Renal Cell | 7 | 2023 | 2321 | 0.900 |
Why?
|
| Positron Emission Tomography Computed Tomography | 6 | 2021 | 845 | 0.900 |
Why?
|
| Hernia, Diaphragmatic | 2 | 2013 | 120 | 0.870 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2021 | 25 | 0.810 |
Why?
|
| Angiomyolipoma | 1 | 2021 | 31 | 0.800 |
Why?
|
| Positron-Emission Tomography | 9 | 2021 | 2182 | 0.800 |
Why?
|
| Faculty | 2 | 2020 | 133 | 0.770 |
Why?
|
| Contrast Media | 9 | 2020 | 1474 | 0.760 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2021 | 1237 | 0.740 |
Why?
|
| Liver Neoplasms | 5 | 2020 | 4563 | 0.740 |
Why?
|
| Tuberous Sclerosis | 1 | 2021 | 135 | 0.720 |
Why?
|
| Leiomyosarcoma | 1 | 2021 | 224 | 0.700 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2020 | 40 | 0.700 |
Why?
|
| Carcinoid Tumor | 2 | 2013 | 280 | 0.670 |
Why?
|
| Meningitis | 2 | 2010 | 112 | 0.660 |
Why?
|
| Teratoma | 1 | 2021 | 235 | 0.660 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2021 | 297 | 0.650 |
Why?
|
| Diagnosis, Differential | 16 | 2021 | 4745 | 0.650 |
Why?
|
| Esophagectomy | 2 | 2013 | 911 | 0.640 |
Why?
|
| Gallbladder Neoplasms | 1 | 2021 | 245 | 0.640 |
Why?
|
| Humans | 92 | 2023 | 262248 | 0.630 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2021 | 328 | 0.620 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2019 | 108 | 0.610 |
Why?
|
| Sarcoidosis | 1 | 2018 | 113 | 0.590 |
Why?
|
| Rectal Neoplasms | 3 | 2019 | 1203 | 0.590 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2018 | 114 | 0.590 |
Why?
|
| Societies, Medical | 10 | 2023 | 1340 | 0.580 |
Why?
|
| Cytogenetic Analysis | 2 | 2021 | 564 | 0.560 |
Why?
|
| Medical Records | 1 | 2017 | 415 | 0.540 |
Why?
|
| Leadership | 1 | 2019 | 253 | 0.540 |
Why?
|
| Ultrasonography | 6 | 2022 | 1869 | 0.530 |
Why?
|
| Adrenocortical Carcinoma | 2 | 2020 | 172 | 0.520 |
Why?
|
| Education, Medical | 1 | 2020 | 348 | 0.520 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 673 | 0.520 |
Why?
|
| Adrenal Cortex Neoplasms | 2 | 2020 | 223 | 0.510 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2018 | 2028 | 0.490 |
Why?
|
| Renal Insufficiency | 2 | 2021 | 321 | 0.480 |
Why?
|
| Students, Medical | 1 | 2020 | 418 | 0.480 |
Why?
|
| Multidetector Computed Tomography | 2 | 2014 | 151 | 0.450 |
Why?
|
| Prostate-Specific Antigen | 1 | 2017 | 999 | 0.450 |
Why?
|
| Sarcoma | 2 | 2021 | 1725 | 0.440 |
Why?
|
| Urogenital System | 1 | 2013 | 59 | 0.440 |
Why?
|
| Calcinosis | 1 | 2016 | 426 | 0.440 |
Why?
|
| Pelvis | 3 | 2022 | 366 | 0.440 |
Why?
|
| Spinal Puncture | 2 | 2010 | 63 | 0.440 |
Why?
|
| Digestive System | 1 | 2013 | 114 | 0.430 |
Why?
|
| Blood Vessels | 2 | 2013 | 217 | 0.430 |
Why?
|
| Genital Neoplasms, Female | 4 | 2021 | 741 | 0.430 |
Why?
|
| Carcinoma, Medullary | 1 | 2013 | 246 | 0.410 |
Why?
|
| Abdomen, Acute | 1 | 2012 | 36 | 0.410 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2019 | 881 | 0.400 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2013 | 362 | 0.380 |
Why?
|
| Forecasting | 1 | 2013 | 695 | 0.370 |
Why?
|
| Hemifacial Spasm | 1 | 2010 | 21 | 0.370 |
Why?
|
| Portal Vein | 1 | 2012 | 356 | 0.360 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 1350 | 0.360 |
Why?
|
| Carcinoma, Papillary | 1 | 2013 | 584 | 0.350 |
Why?
|
| Peritoneal Neoplasms | 1 | 2016 | 828 | 0.340 |
Why?
|
| Medical Oncology | 2 | 2021 | 1424 | 0.340 |
Why?
|
| Intracranial Thrombosis | 1 | 2009 | 17 | 0.340 |
Why?
|
| Precision Medicine | 1 | 2017 | 1160 | 0.340 |
Why?
|
| Defensive Medicine | 1 | 2008 | 8 | 0.330 |
Why?
|
| Anus Neoplasms | 3 | 2023 | 412 | 0.330 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 5124 | 0.330 |
Why?
|
| Lymphoma | 2 | 2016 | 1471 | 0.330 |
Why?
|
| Liver Abscess | 1 | 2008 | 37 | 0.320 |
Why?
|
| Radiotherapy | 2 | 2013 | 1827 | 0.320 |
Why?
|
| Respiratory Sounds | 1 | 2008 | 95 | 0.320 |
Why?
|
| Bronchial Neoplasms | 1 | 2008 | 79 | 0.310 |
Why?
|
| Radiology Information Systems | 2 | 2020 | 114 | 0.310 |
Why?
|
| Embolization, Therapeutic | 1 | 2012 | 552 | 0.310 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 14288 | 0.300 |
Why?
|
| Chest Pain | 1 | 2008 | 156 | 0.300 |
Why?
|
| Female | 30 | 2023 | 142293 | 0.290 |
Why?
|
| Gastrostomy | 1 | 2008 | 180 | 0.290 |
Why?
|
| Sensitivity and Specificity | 8 | 2019 | 4976 | 0.290 |
Why?
|
| Prevalence | 3 | 2020 | 3272 | 0.290 |
Why?
|
| Vena Cava, Inferior | 2 | 2021 | 190 | 0.290 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2015 | 593 | 0.280 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2021 | 489 | 0.280 |
Why?
|
| Radiographic Image Enhancement | 2 | 2020 | 403 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2022 | 10067 | 0.270 |
Why?
|
| Pancreatic Neoplasms | 4 | 2021 | 5100 | 0.270 |
Why?
|
| Cerebellar Neoplasms | 1 | 2010 | 434 | 0.270 |
Why?
|
| Aged | 15 | 2021 | 70367 | 0.260 |
Why?
|
| Venous Thrombosis | 1 | 2009 | 385 | 0.260 |
Why?
|
| Neoplasm Staging | 9 | 2021 | 13669 | 0.250 |
Why?
|
| Adult | 16 | 2022 | 78179 | 0.250 |
Why?
|
| Evidence-Based Medicine | 5 | 2022 | 1101 | 0.250 |
Why?
|
| Molecular Probe Techniques | 2 | 2015 | 46 | 0.250 |
Why?
|
| Molecular Probes | 2 | 2015 | 72 | 0.250 |
Why?
|
| Prostatic Neoplasms | 2 | 2020 | 5778 | 0.240 |
Why?
|
| Middle Aged | 16 | 2020 | 86544 | 0.220 |
Why?
|
| Retrospective Studies | 11 | 2020 | 38011 | 0.220 |
Why?
|
| Molecular Imaging | 2 | 2015 | 185 | 0.220 |
Why?
|
| Thyroid Neoplasms | 1 | 2013 | 1867 | 0.220 |
Why?
|
| Pyelonephritis | 1 | 2022 | 39 | 0.210 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2023 | 82 | 0.210 |
Why?
|
| Population Surveillance | 2 | 2018 | 628 | 0.210 |
Why?
|
| Algorithms | 1 | 2013 | 3890 | 0.210 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2015 | 333 | 0.210 |
Why?
|
| Young Adult | 6 | 2020 | 21494 | 0.210 |
Why?
|
| Radiography, Abdominal | 1 | 2022 | 121 | 0.200 |
Why?
|
| United States | 9 | 2023 | 15574 | 0.200 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2022 | 77 | 0.200 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2021 | 35 | 0.190 |
Why?
|
| Watchful Waiting | 2 | 2022 | 289 | 0.190 |
Why?
|
| Adrenal Gland Diseases | 1 | 2021 | 72 | 0.190 |
Why?
|
| Postoperative Complications | 2 | 2013 | 5567 | 0.190 |
Why?
|
| Male | 17 | 2022 | 123338 | 0.190 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2021 | 108 | 0.190 |
Why?
|
| Abdomen | 3 | 2022 | 332 | 0.180 |
Why?
|
| Vaginal Neoplasms | 1 | 2021 | 148 | 0.180 |
Why?
|
| Cholestasis | 1 | 2022 | 203 | 0.180 |
Why?
|
| Adrenocortical Adenoma | 1 | 2020 | 22 | 0.180 |
Why?
|
| Cysts | 1 | 2021 | 197 | 0.180 |
Why?
|
| Peritoneum | 1 | 2020 | 150 | 0.180 |
Why?
|
| Hematuria | 1 | 2020 | 84 | 0.180 |
Why?
|
| Esophageal Neoplasms | 1 | 2013 | 3170 | 0.180 |
Why?
|
| Neoplasms | 5 | 2023 | 15180 | 0.170 |
Why?
|
| Self-Directed Learning as Topic | 1 | 2019 | 3 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2021 | 481 | 0.170 |
Why?
|
| Adolescent | 6 | 2020 | 31239 | 0.170 |
Why?
|
| Depersonalization | 1 | 2019 | 15 | 0.170 |
Why?
|
| Work-Life Balance | 1 | 2019 | 11 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 2 | 2019 | 3983 | 0.170 |
Why?
|
| Job Satisfaction | 1 | 2020 | 125 | 0.170 |
Why?
|
| United Kingdom | 2 | 2009 | 257 | 0.160 |
Why?
|
| Spleen | 1 | 2020 | 674 | 0.160 |
Why?
|
| Radiology Department, Hospital | 1 | 2019 | 52 | 0.160 |
Why?
|
| Urinary Tract Infections | 1 | 2022 | 324 | 0.160 |
Why?
|
| Occupational Health | 1 | 2018 | 95 | 0.150 |
Why?
|
| Birt-Hogg-Dube Syndrome | 1 | 2017 | 7 | 0.150 |
Why?
|
| Catheters, Indwelling | 1 | 2020 | 375 | 0.150 |
Why?
|
| Prognosis | 5 | 2023 | 21737 | 0.150 |
Why?
|
| Lymphatic Metastasis | 4 | 2019 | 4845 | 0.150 |
Why?
|
| Catheterization, Central Venous | 1 | 2020 | 355 | 0.150 |
Why?
|
| Radiopharmaceuticals | 2 | 2020 | 1308 | 0.150 |
Why?
|
| Imatinib Mesylate | 1 | 2021 | 1665 | 0.150 |
Why?
|
| Terminology as Topic | 1 | 2019 | 417 | 0.150 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 5724 | 0.150 |
Why?
|
| Education, Medical, Continuing | 1 | 2019 | 256 | 0.140 |
Why?
|
| Hemorrhage | 1 | 2021 | 715 | 0.140 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2017 | 54 | 0.140 |
Why?
|
| Mesentery | 1 | 2016 | 72 | 0.140 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 29996 | 0.140 |
Why?
|
| Risk Factors | 4 | 2021 | 17622 | 0.130 |
Why?
|
| Mesenchymoma | 1 | 2015 | 14 | 0.130 |
Why?
|
| Intestinal Diseases | 1 | 2016 | 121 | 0.130 |
Why?
|
| Brain | 1 | 2008 | 4097 | 0.130 |
Why?
|
| Liver | 2 | 2018 | 2904 | 0.120 |
Why?
|
| Curriculum | 1 | 2020 | 868 | 0.120 |
Why?
|
| Health Promotion | 1 | 2018 | 504 | 0.120 |
Why?
|
| Renal Veins | 1 | 2014 | 56 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 2334 | 0.120 |
Why?
|
| Pancreatic Diseases | 1 | 2015 | 108 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 3263 | 0.120 |
Why?
|
| Gene Fusion | 1 | 2015 | 209 | 0.120 |
Why?
|
| Nephrectomy | 2 | 2019 | 779 | 0.110 |
Why?
|
| Triiodobenzoic Acids | 1 | 2013 | 68 | 0.110 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 6046 | 0.110 |
Why?
|
| Biomarkers | 2 | 2015 | 5055 | 0.110 |
Why?
|
| Incidence | 2 | 2013 | 5713 | 0.110 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2015 | 221 | 0.110 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2015 | 341 | 0.110 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 4337 | 0.110 |
Why?
|
| Radionuclide Imaging | 1 | 2013 | 654 | 0.100 |
Why?
|
| Meningocele | 1 | 2012 | 20 | 0.100 |
Why?
|
| Hemangiosarcoma | 1 | 2014 | 235 | 0.100 |
Why?
|
| Treatment Outcome | 5 | 2020 | 33028 | 0.100 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2013 | 192 | 0.100 |
Why?
|
| Genomics | 2 | 2020 | 2744 | 0.100 |
Why?
|
| Image Enhancement | 1 | 2015 | 562 | 0.100 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2015 | 661 | 0.100 |
Why?
|
| Cerebellopontine Angle | 1 | 2010 | 12 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 4386 | 0.090 |
Why?
|
| Uterine Neoplasms | 1 | 2015 | 549 | 0.090 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2015 | 362 | 0.090 |
Why?
|
| Anal Canal | 2 | 2023 | 237 | 0.090 |
Why?
|
| Incidental Findings | 1 | 2012 | 272 | 0.090 |
Why?
|
| Mass Screening | 1 | 2018 | 1506 | 0.090 |
Why?
|
| Biopsy | 1 | 2017 | 3447 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 2420 | 0.080 |
Why?
|
| Proteomics | 1 | 2015 | 1386 | 0.080 |
Why?
|
| Intracranial Pressure | 1 | 2009 | 180 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 15874 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 2480 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2023 | 14913 | 0.080 |
Why?
|
| Fluoroscopy | 1 | 2008 | 232 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 1759 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2012 | 927 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 5538 | 0.080 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 587 | 0.070 |
Why?
|
| Nervous System Malformations | 1 | 2008 | 133 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2020 | 3347 | 0.070 |
Why?
|
| Thorax | 2 | 2021 | 213 | 0.070 |
Why?
|
| Radiography, Interventional | 1 | 2008 | 306 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2015 | 2362 | 0.070 |
Why?
|
| Patients | 1 | 2008 | 251 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 5435 | 0.070 |
Why?
|
| Bronchoscopy | 1 | 2008 | 475 | 0.060 |
Why?
|
| Radiation Injuries | 1 | 2012 | 1412 | 0.060 |
Why?
|
| Mutation | 2 | 2021 | 15167 | 0.060 |
Why?
|
| Toes | 1 | 2023 | 46 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2009 | 683 | 0.060 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 10348 | 0.050 |
Why?
|
| Liver Cirrhosis | 2 | 2022 | 945 | 0.050 |
Why?
|
| Bile Ducts | 1 | 2022 | 112 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 2633 | 0.050 |
Why?
|
| Decision Making | 1 | 2009 | 1295 | 0.050 |
Why?
|
| Adrenal Glands | 1 | 2021 | 122 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 7793 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2012 | 1416 | 0.050 |
Why?
|
| Bevacizumab | 2 | 2015 | 938 | 0.050 |
Why?
|
| Models, Immunological | 1 | 2020 | 79 | 0.040 |
Why?
|
| Molecular Biology | 1 | 2021 | 175 | 0.040 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2020 | 47 | 0.040 |
Why?
|
| Injections | 1 | 2020 | 286 | 0.040 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2020 | 98 | 0.040 |
Why?
|
| Time Factors | 1 | 2013 | 12984 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2023 | 1034 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2013 | 12923 | 0.040 |
Why?
|
| Quality Control | 1 | 2019 | 459 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 3975 | 0.040 |
Why?
|
| Radiation Dosage | 1 | 2022 | 1016 | 0.040 |
Why?
|
| Rectum | 1 | 2019 | 469 | 0.040 |
Why?
|
| Equipment Design | 1 | 2020 | 1208 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 1181 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 503 | 0.030 |
Why?
|
| Motivation | 1 | 2019 | 510 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2015 | 68 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 1363 | 0.030 |
Why?
|
| Consensus | 1 | 2019 | 1005 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2016 | 232 | 0.030 |
Why?
|
| Hemangioma, Cavernous | 1 | 2014 | 27 | 0.030 |
Why?
|
| Prostate | 1 | 2020 | 1090 | 0.030 |
Why?
|
| Capecitabine | 1 | 2015 | 388 | 0.030 |
Why?
|
| Communication | 1 | 2021 | 883 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 2014 | 418 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2020 | 1991 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 389 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2021 | 929 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2015 | 704 | 0.030 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 2012 | 16 | 0.030 |
Why?
|
| Spinal Curvatures | 1 | 2012 | 4 | 0.030 |
Why?
|
| Ileus | 1 | 2012 | 27 | 0.030 |
Why?
|
| Child | 2 | 2015 | 29067 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2008 | 16213 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 2302 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 4903 | 0.020 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2012 | 111 | 0.020 |
Why?
|
| Pancreas | 1 | 2015 | 717 | 0.020 |
Why?
|
| Neurofibromatosis 1 | 1 | 2012 | 144 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 2012 | 201 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 2804 | 0.020 |
Why?
|
| Pancreatitis | 1 | 2012 | 269 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 3755 | 0.020 |
Why?
|
| Gastroenteritis | 1 | 2012 | 303 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 2860 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 1541 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 767 | 0.020 |
Why?
|
| Disease Progression | 1 | 2020 | 6693 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 7545 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 3233 | 0.020 |
Why?
|
| Neutropenia | 1 | 2012 | 965 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 1900 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2012 | 697 | 0.020 |
Why?
|
| Animals | 3 | 2020 | 59489 | 0.020 |
Why?
|
| Liver Diseases | 1 | 2012 | 570 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 1247 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2013 | 2969 | 0.010 |
Why?
|
| Mice | 1 | 2020 | 34393 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2015 | 11972 | 0.010 |
Why?
|